ArticleCureus2025
The Safety of Nebulized Conjugated Linoleic Acid for COVID-19 Respiratory Tract Infections.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linoleic acid is an essential fatty acid, and in 2007, the US FDA listed conjugated linoleic acid (CLA) isomers as generally recognized as safe (GRAS) for human consumption. The potassium salt of conjugated linoleic acid (K-CLA) exhibits broad-spectrum antimicrobial activity. K-CLA also possesses mucolytic properties. This study reviewed the safety of nebulized K-CLA for COVID-19-related respiratory tract infections early during the pandemic. Among 57 treated subjects, adverse events leading to treatment discontinuation occurred in three patients. Two reported an increased cough, and the other reported nausea with emesis. Of the 57 patients treated, 25 were hypoxic during their infection, and 18 of the 25 reported benefits with dyspnea and/or pulse oximetry after initiation of nebulized K-CLA. This retrospective case series provides initial human safety data and describes observed clinical outcomes in subjects treated with nebulized K-CLA, supporting the need for prospective controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.